Literature DB >> 17380108

Racial differences in trends of end-stage renal disease, by primary diagnosis--United States, 1994-2004.

.   

Abstract

The leading cause of end-stage renal disease (ESRD) (i.e., kidney failure requiring dialysis or transplantation) in the United States is diabetes, followed by hypertension and glomerulonephritis. These three conditions accounted for approximately 80% of new cases of ESRD treated during 2004. This report presents an analysis of data from the United States Renal Data System (USRDS) to examine trends in the primary diagnosis of ESRD in the United States. The findings of that analysis indicated that, during 1994-2004, ESRD incidence attributed to glomerulonephritis decreased among all races analyzed. During 1999-2004, ESRD incidence attributed to diabetes or hypertension also decreased for American Indians/Alaska Natives (AI/ANs) and Asians/Pacific Islanders (A/PIs) but not for whites or blacks. Continued interventions, such as those addressing blood-glucose and blood-pressure control, are needed to reduce the prevalence of these risk factors for kidney failure and to improve care among persons with these conditions.

Entities:  

Mesh:

Year:  2007        PMID: 17380108

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  10 in total

1.  The costs of treating American Indian adults with diabetes within the Indian Health Service.

Authors:  Joan M O'Connell; Charlton Wilson; Spero M Manson; Kelly J Acton
Journal:  Am J Public Health       Date:  2011-12-15       Impact factor: 9.308

2.  An explorative analysis of secretory receptor for advanced glycation endproducts in primary focal segmental glomerulosclerosis.

Authors:  Harin Rhee; Sang Heon Song; Ihm Soo Kwak; Il Young Kim; Eun Young Seong; Dong Won Lee; Soo Bong Lee
Journal:  Clin Exp Nephrol       Date:  2012-08       Impact factor: 2.801

3.  Pandemic influenza preparedness and vulnerable populations in tribal communities.

Authors:  Amy V Groom; Cheyenne Jim; Mic Laroque; Cheryl Mason; Joe McLaughlin; Lisa Neel; Terry Powell; Thomas Weiser; Ralph T Bryan
Journal:  Am J Public Health       Date:  2009-05-21       Impact factor: 9.308

4.  Hypertension during pregnancy is associated with coronary artery calcium independent of renal function.

Authors:  Andrea E Cassidy-Bushrow; Lawrence F Bielak; Andrew D Rule; Patrick F Sheedy; Stephen T Turner; Vesna D Garovic; Patricia A Peyser
Journal:  J Womens Health (Larchmt)       Date:  2009-10       Impact factor: 2.681

5.  Impact of Medicare coverage on disparities in access to simultaneous pancreas and kidney transplantation.

Authors:  J K Melancon; L M Kucirka; L E Boulware; N R Powe; J E Locke; R A Montgomery; D L Segev
Journal:  Am J Transplant       Date:  2009-10-21       Impact factor: 8.086

Review 6.  Chronic kidney disease perspectives in Japan and the importance of urinalysis screening.

Authors:  Kunihiro Yamagata; Kunitoshi Iseki; Kousaku Nitta; Hirokazu Imai; Yasuhiko Iino; Seiichi Matsuo; Hirofumi Makino; Akira Hishida
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

7.  ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized?

Authors:  Lamioko Shika Pappoe; Wolfgang C Winkelmayer
Journal:  Drugs Aging       Date:  2010-02-01       Impact factor: 3.923

8.  Optimizing care in diabetes: a quixotic challenge.

Authors:  Eli A Friedman
Journal:  Diabetes Care       Date:  2012-06       Impact factor: 19.112

Review 9.  Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.

Authors:  Gianpaolo Reboldi; Giorgio Gentile; Fabio Angeli; Paolo Verdecchia
Journal:  Vasc Health Risk Manag       Date:  2009

10.  End-stage renal disease in Taiwan: a case-control study.

Authors:  Su-Ying Tsai; Hung-Fu Tseng; Hsiu-Fen Tan; Yu-Shu Chien; Chia-Chu Chang
Journal:  J Epidemiol       Date:  2009-06-20       Impact factor: 3.211

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.